Total abrogation of collagen II-induced XXXX and the B cell response to type II collagen using suboptimal doses of a topoisomerase II antagonist.

@entity625 @entity19 @entity60 @entity1753 @entity2879 @entity1391 @entity309
BACKGROUND: @entity1753 ( @entity1753 ) is the most commonly used model of @entity309 ( @entity309 ). In both @entity1753 and @entity309 there is an increase in the cellular content of the synovium, this being dominated by macrophages. OBJECTIVE: To assess the impact of @entity2879 , a topoisomerase II antagonist known to induce monocyte apoptosis, on the development of @entity1753 . METHODS: @entity19 were primed and booster immunised against collagen II (CII). One group of @entity19 was treated with @entity2879 two days before CII immunisation and then on four consecutive days weekly until the end of the experiment. The second group of @entity19 was injected with @entity2879 on four consecutive days a week starting 40 days after CII priming. The third group of @entity19 were controls receiving @entity1391 buffered saline (PBS). The @entity19 were examined for development of @entity625 , numbers of circulating leucocytes, serum CII antibody, and cytokine concentrations. RESULTS: None of the @entity19 given @entity2879 before CII immunisation developed @entity625 . Serum concentrations of anti-CII antibodies were undetectable in these @entity19 , whereas they displayed significantly increased concentrations of @entity60 . In addition, the CII specific B cell responses in the draining lymph nodes were highly suppressed. Also, @entity19 treated with @entity2879 at the onset of clinical @entity625 showed reduced frequency of their disease by 50%. CONCLUSION: There was a striking disease alleviating impact of topoisomerase II antagonist on the course of CII-induced @entity625 .
